San Francisco, CANCT07033689Now EnrollingIRB Ready

Pancreatic Cancer Clinical Trial in San Francisco, CA

Access cutting-edge pancreatic cancer treatment through this early phase 1 clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by SONIRE Therapeutics Inc.

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access pancreatic cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic cancer treatment provided free

Apply for This San Francisco Location

Check if you qualify for this pancreatic cancer clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Pancreatic Cancer Study in San Francisco

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

Sponsor: SONIRE Therapeutics Inc.

Who Can Participate

Inclusion Criteria

Signed an Institutional Review Board (IRB) approved informed consent document.
Men and women ≥ 18 years of age.
Histologically or cytologically diagnosed PDAC.
Newly diagnosed unresectable\*, locally advanced or metastatic disease. (\
defined as not "Resectable" and not "borderline resectable" based on "Criteria Defining Resectability at Diagnosis" in NCCN Guideline 2024)
Primary tumor accessible to HIFU treatment and visualized on transabdominal ultrasonography.
Primary tumor site must be a measurable lesion according to RECIST version 1.1 at baseline.
ECOG Performance Status (ECOG-PS) of 0 - 1.
Life expectancy ≥ 3 months.
Adequate organ function defined by:
Neutrophil count: ≥ 1,500/mm3
Platelet count: ≥ 50,000/mm3
Hemoglobin: ≥ 8.0 g/dl
Cr: ≤ 1.7 mg/dl
AST, ALT: ≤ 3 x upper limit of normal
T-Bil: ≤ 2 x upper limit of normal Exclusion Criteria:
Subjects with any cancers other than PDAC who are on active treatment.
Subjects who had any prior chemotherapy or interventions for PDAC.
Obstructive jaundice (except for subjects who have a bile duct stent placed for obstructive jaundice prior to initiation of HIFU treatment).
Tumor embolization in the veins surrounding the pancreas.
Cysts outside of primary pancreatic tumor which may obstruct the HIFU sonication pathway. However, if the cyst is completely surrounded by pancreatic tumor, the subject can be included.
Subjects with \> 50% reduction in caliber of the principal hepatic artery and occlusion of the portal vein seen on preoperative screening CT or MRI scan.
Allergy to contrast agents (except when manageable by prophylactic steroid).
Subjects having a cardiac pacemaker.
Congestive heart failure, symptomatic coronary artery disease, arrhythmia poorly controlled by drugs, history of myocardial infarction or unstable angina within the past 6 months.
Subjects with peritoneal dissemination.
Active infections requiring systemic treatment.
Pregnancy or women of childbearing potential not willing to follow the birth control as described in the informed consent and/or who are breastfeeding.
Received unapproved or investigational drug or device within 30 days of the subject's study start date.
The judgment of the investigator would make the subject inappropriate for entry into the study.

Exclusion Criteria

Subjects with any cancers other than PDAC who are on active treatment.
Subjects who had any prior chemotherapy or interventions for PDAC.
Obstructive jaundice (except for subjects who have a bile duct stent placed for obstructive jaundice prior to initiation of HIFU treatment).
Tumor embolization in the veins surrounding the pancreas.
Cysts outside of primary pancreatic tumor which may obstruct the HIFU sonication pathway. However, if the cyst is completely surrounded by pancreatic tumor, the subject can be included.
Subjects with \> 50% reduction in caliber of the principal hepatic artery and occlusion of the portal vein seen on preoperative screening CT or MRI scan.
Allergy to contrast agents (except when manageable by prophylactic steroid).
Subjects having a cardiac pacemaker.
Congestive heart failure, symptomatic coronary artery disease, arrhythmia poorly controlled by drugs, history of myocardial infarction or unstable angina within the past 6 months.
Subjects with peritoneal dissemination.
Active infections requiring systemic treatment.
Pregnancy or women of childbearing potential not willing to follow the birth control as described in the informed consent and/or who are breastfeeding.
Received unapproved or investigational drug or device within 30 days of the subject's study start date.
The judgment of the investigator would make the subject inappropriate for entry into the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT07033689) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Cancer Treatment Options in San Francisco, CA

If you're searching for pancreatic cancer treatment options in San Francisco, CA, this clinical trial (NCT07033689) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic cancer clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in San Francisco, CA

See all pancreatic cancer clinical trials recruiting in San Francisco — not just this study.

Browse Pancreatic Cancer Trials in San Francisco →

Browse More Trials by Condition

Pancreatic Cancer TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA